Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  SenzaGen AB    SENZA   SE0010219626

SENZAGEN AB

(SENZA)
  Report
End-of-day quote. End-of-day quote NASDAQ OMX STOCKHOLM - 10/23
20.4 SEK   -0.49%
09/16SENZAGEN : Global medical device company places SEK 0.6 million order
AQ
09/11SENZAGEN : receives order for GARD™skin and GARD™potency from a major US chemical company
AQ
SummaryChartsNewsCompanyFinancials 
Business Summary
SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.

Number of employees : 23 people.
Sales per Business
20182019Delta
SEK (in Million)%SEK (in Million)%
Genomic Allergen Rapid Detection2.00100%2.72100% +36.4%
Sales per region
20182019Delta
SEK (in Million)%SEK (in Million)%
Sweden2.00100%2.72100% +36.4%
Managers
NameAgeSinceTitle
Axel Sjöblad522019Chief Executive Officer
Karl Arne Krister Borrebaeck, Dr.712011Chairman
Marianne Olsson582016Chief Financial Officer
Gunilla Grundström, Dr.-2018Chief Scientific Officer
Ann Ulrika Gidner532014Director
Cecilia Ann-Christin Malmborg Hager, Dr.542019Director
Ian Kimber, Dr.-2015Director
Laura Chirica, Dr.512017Director
Peter Nählstedt45-Director
Peter Sandberg, Dr.--Director-Sales & Marketing
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 21,357,636 17,984,571 84.2% 0 0.0% 84.2%
Shareholders
NameEquities%
Karl Arne Krister Borrebaeck 1,732,100 8.11%
Malin Marie Lindstedt 1,655,744 7.75%
Erwin Roggen 658,374 3.08%
Fjärde AP-fonden 530,503 2.48%
Delcea AB 401,837 1.88%
Cecilia Ann-Christin Malmborg Hager 392,541 1.84%
Nordea Investment Management AB 347,091 1.63%
Anna Cherouvrier Hansson 15,650 0.073%
Peter Nählstedt 1,622 0.0076%
Company contact information
SenzaGen AB
Medicon Village
Building 406
Scheelevägen 2
Lund, Skane 223 81

Phone : +46.46.2756200
Web : http://www.senzagen.com
Sector Bio Diagnostics & Testing
1st jan.Capitalization (M$)
SENZAGEN AB9.86%50
EXACT SCIENCES CORPORATION15.80%16 081
GUARDANT HEALTH, INC.31.42%10 230
BGI GENOMICS CO., LTD.100.82%8 175
ADAPTIVE BIOTECHNOLOGIES CORPORATION56.85%6 373
SEEGENE INC--.--%6 224
INVITAE CORPORATION185.24%6 063
IOVANCE BIOTHERAPEUTICS, INC.32.77%5 382
CAREDX, INC135.28%2 485
VERACYTE, INC.39.86%2 210
Q-LINEA AB (PUBL)149.57%442
BIOVICA INTERNATIONAL AB (PUBL)200.00%114
EPIGENOMICS AG-45.05%42